Approval of omaveloxolone for Friedreich ataxia

IF 28.2 1区医学 Q1 CLINICAL NEUROLOGY

Nature Reviews Neurology Pub Date : 2024-04-03 DOI:10.1038/s41582-024-00957-9

Sylvia Boesch, Elisabetta Indelicato

引用次数: 0

Abstract

The recent approval of omaveloxolone for the treatment of Friedreich ataxia in the USA and Europe represents an important milestone in the field of rare neurological diseases. However, many challenges lie ahead, including the translation of trial results into clinical practice, and the management of patients’ expectations.

查看原文本刊更多论文

批准奥马韦洛酮治疗弗里德里希共济失调症

最近，美国和欧洲批准使用奥马韦洛酮治疗弗里德里希共济失调症，这是罕见神经疾病领域的一个重要里程碑。然而，未来还有许多挑战，包括如何将试验结果转化为临床实践，以及如何满足患者的期望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Neurology 医学-临床神经学

CiteScore

29.90

自引率

0.80%

发文量

138

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Neurology aims to be the premier source of reviews and commentaries for the scientific and clinical communities we serve. We want to provide an unparalleled service to authors, referees, and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians working in the field of neurology. Our broad scope ensures that the work we publish reaches the widest possible audience. Our articles are authoritative, accessible, and enhanced with clearly understandable figures, tables, and other display items. This page gives more detail about the aims and scope of the journal.